# Albert Tae

# Asia Pacific Counsel, Seoul

International Litigation and Arbitration



T: 82.2.6177.3004 albert.tae@skadden.com

#### Education

J.D., University of La Verne, 2006 LL.B., Yonsei University, 1997

## **Bar Admissions**

California Foreign Legal Consultant Korea Texas District of Columbia

## Languages

English Korean Albert Tae's practice focuses on complex cross-border litigation, in particular cross-border matters involving Korea and the United States.

Mr. Tae has represented companies in various disputes in the financial services, pharmaceutical, manufacturing and other industries. He advises on commercial litigation, class action litigation, intellectual property litigation, international arbitration and electronic discovery.

His practice encompasses general corporate matters for public and private entities, including cross-border corporate transactions and regulatory compliance matters.

Mr. Tae's recent experience (including experience prior to Skadden) includes representing:

- a large Korean company in international arbitration proceedings in Singapore regarding defective heat exchange equipment supplied by a large American company
- a large Korean company in a significant international arbitration matter in Singapore regarding misconduct by a retail clothing franchisor
- Kia Motors Corporation in connection with a significant trademark infringement action
- Tom N Toms Coffee in arbitration regarding multiple breaches of franchise agreements
- a Korean financial institution in an investigation by the U.S. Department of Justice
- a Korean medical device manufacturing company in an arbitration relating to a breach of contract
- a Korean automobile company in a patent infringement case filed by a non-practicing entity ("patent troll")
- Woori Bank in securing the dismissal of claims exceeding €8 billion in an action in the Southern District of New York
- Celltrion Healthcare in connection with preparing a global compliance program
- SillaJen, Inc., a Korean biotechnology company, in its acquisition of Jennerex, Inc., a U.S. biotechnology company, including with regard to FDA-related legal matters

